698387-09-6

Neratinib is an antineoplastic drug CAS:698387-09-6

Neratinib is a tyrosine kinase inhibitor. On July 17, 2017, the FDA approved its extended adjuvant therapy for early-stage HER2-positive breast cancer. Neratinib was the first extended adjuvant therapy for this type of cancer.

Detailed Photos

 

    Hebei Lingding Biotechnology Co., Ltd. is a professional business company ,that include pharmaceutical raw materials, pharmaceutical intermediates,and other more than 1000 products of the enterprise,  The registered capital is 3 million yuan, it is a collection of scientific research, production and sales in one of the enterprises.

Since its establishment, the company has always adhered to the core concept of "focus on products, attentive service", adhere to the business purpose of "innovation, professional, win-win", to provide customers with a full range of meticulous and thoughtful services. We will adhere to the customer's serious and responsible attitude, comply with the standardized operation procedures, with efficient execution to complete customer needs.

The company's products are sold all over the world, mainly exported to the United States, Europe, Southeast Asia, Australia, the Middle East and South Africa and other countries.The company has a strong scientific research and technical team, can provide customers with high quality products and a full range of services. We will provide first-class products and better service to face the needs of customers, to meet the challenges of the market.  Welcome domestic and foreign customers to negotiate.

1.Any inquiry or message will be replied within 12 hours.
2.Professional manufacturer. Welcome to visit our website.
3.API, Intermediate are available, we can offer Custom Synthesis, and registration as well.
4.Fast delivery.
5.After-sale services